Gufic Biosciences Ltd
GUFICBIO
Company Profile
Business description
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare, Criticare Life, Ferticare, Spark, Herbal, and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral, and a proton-pump inhibitor. It derives maximum revenue from India.
Contact
SM House, 11 Sahakar Road
1st to 4th Floor
Vile Parle (East)
MumbaiMH400 057
INDT: +91 2267261000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
2,926
Stocks News & Analysis
stocks
The trillion-dollar club: Are these mega-sized stocks still buys?
The biggest stocks got bigger this year, breaking multi-trillion-dollar milestones.
stocks
New pricing model for embattled ASX tech leader
Investor day shows off potentially disruptive pricing model.
stocks
Chart of the Week: We see opportunity in Mineral Resources despite debt concerns
Shares trade at a discount despite attractive longer-term outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,926.10 | 19.30 | 0.22% |
| CAC 40 | 8,114.74 | 7.29 | -0.09% |
| DAX 40 | 24,028.14 | 146.11 | 0.61% |
| Dow JONES (US) | 47,954.99 | 104.05 | 0.22% |
| FTSE 100 | 9,667.01 | 43.86 | -0.45% |
| HKSE | 26,085.08 | 149.18 | 0.58% |
| NASDAQ | 23,578.13 | 72.99 | 0.31% |
| Nikkei 225 | 50,491.87 | 536.55 | -1.05% |
| NZX 50 Index | 13,483.99 | 31.63 | -0.23% |
| S&P 500 | 6,870.40 | 13.28 | 0.19% |
| S&P/ASX 200 | 8,634.60 | 20.50 | 0.24% |
| SSE Composite Index | 3,902.81 | 27.01 | 0.70% |